Novaccess Global Inc XSNX

Healthcare Biotechnology

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

OTCPK:XSNX - Post by User

Novaccess Global Inc > PATIENCE

<< Previous

Bullboard Posts

Next >>

Comment by LittleFundson Feb 05, 2018 8:56pm

195 Views

Post# 27508193

RE:RE:PATIENCE

I guess it all really depends on how you look at it.. Im new to this, so maybe im wrong?? but, the run we had at the beginning of the year was 300% + gains.. id say thats pretty big.. why does it need to be above .4?? If we go from 0.0012 - 0.02 id consider that huge lol... what am i missing??

<< Previous

Bullboard Posts

Next >>

First Helium advances winter drilling program with Leduc Anomaly test well